Dr. Ntanios disagrees with my comment that "most studies have shown the greater potency of plant stanols in lowering serum cholesterol" and cites one published study (Westrate and Meijer 1998) and one abstract. Westrate and Meijer compared the efficacy of the "esterified" forms of sterol and stanol and not the "free" forms, which may be an important distinction in terms of cholesterol-lowering efficacy. These data are interesting but did not provide a "clean" comparison because the amount of sterols in the sterol ester margarine differed from the amount of stanols in the stanol ester margarine. There were also differences in the fat composition of the margarines. Dr. Ntanios' current position seems to contradict his conclusions in two previous reviews he coauthored (Jones et al. 1997, Jones and Ntanios 1998) , where he stated that the result in the Westrate and Meijer study "is in contrast to the results of other studies that have compared the relative efficacy of the action of plant sterols vs. stanols and have concluded that the latter is more than twofold more potent as a cholesterol-lowering agent." No new evidence has surfaced to change the validity of this conclusion.
Dr. Ntanios disagrees that plant sterols can be atherogenic even in phytosterolemic patients. However, the atherogenic potential of plant sterols is supported (Salen et al. 1999 ) by the fact that (i) monocytes, the precursors of foam cells, can accumulate plant sterols; (ii) in a phytosterolemic patient who died of cardiac sudden death, increased plant sterols amounts were found in the heart-replacing cholesterol; and (iii) treatment with bile acid malabsorption lowers plasma sterol levels, improving cardiac symptoms.
In phytosterolemic patients with accelerated atherosclerosis reported that plasma sisterol and campesterol levels can be as low as 7.5 and 2.1 mg/dl, respectively, while plasma cholesterol levels are frequently not elevated. Dr. Ntanios disagrees with the concern that even a small increase in blood levels of plant sterols may be atherogenic in hypercholesterolemic patients, based on the findings by Glueck et al. (1991) . However, Dr. Ntanios' current position again contradicts his previous conclusion (Jones et al. 1997) , that "elevated absorption of phytosterol in hypercholesterolemic individuals may identify those individuals . . . at increased risk for premature CHD" and that "intervention for these individuals may also include reduced sources of phytosterol-enriched foods." The implication by Dr. Ntanios that long-term safety is not an issue because plant sterols "have been part of the human diet for millennia" is misleading. The typical Western intake of plant sterols is 200 -300 mg/d, significantly less than the 2000 -3000 mg/d required to lower serum cholesterol. Westrate and Meijer (1998) showed that consumption of 3000 mg/d of plant sterol esters increases plasma plant sterols levels, and especially campesterol by an average of 70%. No actual range of absolute plasma sterol levels attained was given. Thus, additional studies are required to determine the long-term significance of this elevation in plasma campesterol and sitosterol levels. In contrast to plant sterols, plant stanols are practically nonabsorbable (Grundy 1999 ) and lead to a marked decrease in the blood levels of these plant sterols. This advantage of plant stanols was even pointed out previously by Dr. Ntanios (Jones and Ntanios 1998) , that "stanols are also not absorbed, and thus protect against the potential sterol accumulation associated with ␤ sitosterolemia."
The safety data by Baker et al. (1999) showed no evidence of estrogenic effect by plant sterols; however, Gaido et al. (1996) showed that highly pure sitosterol was weakly estrogenic in the same recombinant human estrogen receptor (hER) yeast strain. Both studies only tested binding to the recombinant hER subtype, hER␣. Phytoestrogens appear to have greater binding affinity to another hER subtype, hER␤ (Kuiper et al. 1998 ). There are no data on binding of plant sterols to hER␤.
In summary, the shift in the focus of research from plant sterols to plant stanols was prompted for the following reasons: (i) Prior evidence suggests that they were more effective inhibitors of cholesterol absorption than plant sterols. The 14 studies in Table 1 along with five newer ones confirm that plant stanols esters are efficacious in lowering serum cholesterol levels. There are currently too few studies (two published) with plant sterol esters to determine their range of efficacy. More studies are needed to define precisely their relative potencies compared to plant stanol esters. (ii) Historically there has been concern about recommending plant sterol-enriched products to hypercholesterolemic patients since plant sterols, in particular campesterol, can be atherogenic when absorbed. In contrast, plant stanols were found to be virtually nonabsorbable, a property that greatly enhances their safety. Relationships of serum plant sterols (phytosterols) and cholesterol in 595 hypercholesterolemic subjects, and familial aggregation of phytosterols, cholesterol and premature coronary heart disease in hyperphytosterolemic probands and their first-degree relatives. Metabolism 40: 842-848.
